What is the market cap of Kbio Labs?

The market capitalisation of Kbio Labs was ₩16B at the close on Oct 27, 2026.

Who are the largest shareholders of Kbio Labs?

According to the latest official filings, the largest reported holders are Mirae I&G (40.99%, as of Sep 4, 2026); Fantasio (5.51%, as of Apr 23, 2026).

When is the next earnings report from Kbio Labs?

Korean companies rarely announce results dates in advance. Based on when Kbio Labs filed the same report in past years, its next 3q results is expected around Nov 14, 2026.

KOSDAQ · 038530 · Retail & Trade · ₩038530

Kbio Labs케이바이오랩스

038530 · KOSDAQ · ₩038530 · 케이바이오랩스

₩3,065▲ ₩140 (4.79%)End-of-day · Oct 27, 2026 · End-of-day prices.

Trade

Price · 1Y −48.49%

Market cap: ₩16B
Enterprise value: ₩1.4B
P/E: —
P/B: 0.4×
Dividend yield: 0.0%
ROE: −37.3%
Net margin: −22.0%

Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.

52-week range−77.7% from the high

₩2,925Today: ₩2,925 – ₩3,135₩13,751

Returns

1W−7.5%
1M−24.7%
3M−21.4%
6M−60.5%
YTD−49.1%
1Y−48.5%

Volume today: 14,097; 1.2× the 20-day average
Traded today: ₩42M
Listed shares: 5,178,024
EPS (12 months): −₩2,874; Earnings yield −93.8%

Sell Buy

AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.

Upcoming dates

Nov 16Earnings Expected · 3Q results

Full calendar →

🎁 Gift this stock

Send a friend ₩100,000 of paper money in this stock. They get it when they join.

X f WA TG r/in @

Signals

Quiet

BuzzQuietBuzz 44 of 100 (50 is a normal day for this stock).
MomentumWeak-28.6% over the last month; the price is below its 20-day average.

Signals describe activity, not recommendations. Not financial advice.

Kbio Labs stock overview

Kbio Labs (케이바이오랩스, KRX: 038530) is listed on KOSDAQ, in the Retail & Trade sector. The company distributes life science equipment, reagents and consumables to universities, hospitals, research labs and other clients through its bio distribution business, which it began in November 2021 by acquiring the distribution division of Cure Bio, and it also operates an ICT business in hardware, software and IT services. Its shares closed at ₩3,065 on Oct 27, 2026, up 4.79% on the day, giving it a market value of ₩16B.

Market cap: ₩16B
Sector: Retail & Trade
Latest price change: +4.79%
As of: Oct 27, 2026
Main business: The company distributes life science equipment, reagents and consumables to universities, hospitals, research labs and other clients through its bio distribution business, which it began in November 2021 by acquiring the distribution division of Cure Bio, and it also operates an ICT business in hardware, software and IT services.

Quick answers about Kbio Labs

What does Kbio Labs do?: The company distributes life science equipment, reagents and consumables to universities, hospitals, research labs and other clients through its bio distribution business, which it began in November 2021 by acquiring the distribution division of Cure Bio, and it also operates an ICT business in hardware, software and IT services. The ICT business, rooted in video security, develops and sells CCTV storage devices, security cameras and IoT-based solutions such as integrated control systems, GIS mapping, smart police and safe-return services. Its operations centre on the Seoul and Gyeonggi area, with bio products sold under partnerships with global brands such as Thermo Fisher and Merck, and ICT products sold domestically and overseas, including through a branch in the United States.
What is the market cap of Kbio Labs?: The market capitalisation of Kbio Labs was ₩16B at the close on Oct 27, 2026.
Who are the largest shareholders of Kbio Labs?: According to the latest official filings, the largest reported holders are Mirae I&G (40.99%, as of Sep 4, 2026); Fantasio (5.51%, as of Apr 23, 2026).
When is the next earnings report from Kbio Labs?: Korean companies rarely announce results dates in advance. Based on when Kbio Labs filed the same report in past years, its next 3q results is expected around Nov 14, 2026.

Company profile

The company distributes life science equipment, reagents and consumables to universities, hospitals, research labs and other clients through its bio distribution business, which it began in November 2021 by acquiring the distribution division of Cure Bio, and it also operates an ICT business in hardware, software and IT services. The ICT business, rooted in video security, develops and sells CCTV storage devices, security cameras and IoT-based solutions such as integrated control systems, GIS mapping, smart police and safe-return services. Its operations centre on the Seoul and Gyeonggi area, with bio products sold under partnerships with global brands such as Thermo Fisher and Merck, and ICT products sold domestically and overseas, including through a branch in the United States.

Written by AI from the company's latest annual report.

Korean name: 케이바이오랩스
Sector: Retail & Trade
Themes: Biotech (new drugs)
CEO: 조안협, 이영철
Founded: Jun 1997
Listed: Jun 2000
Listed shares: 5,178,024
Fiscal year ends: Month 12
Website: www.kbiocompany.com

Similar companies

Samsung C&T028260 · ₩49T₩301,000+3.08%
POSCO International047050 · ₩8.8T₩49,850+0.61%
ISC095340 · ₩3.2T₩151,300+7.61%
Youngone111770 · ₩3T₩68,100+1.04%
Dong SUH Companies026960 · ₩2.7T₩27,500+0.73%
Shinsegae004170 · ₩2.3T₩245,0000.00%
SK Gas018670 · ₩2.3T₩249,000−0.80%
Lotte Shopping023530 · ₩2.3T₩81,300−0.12%

Recent filings

See all

Titles in Korean until English translations are added.

Also known as: Kbio Labs / 케이바이오랩스 / 038530 / KRX:038530

Source: KRX statistical information